Latest Biotech News

Merck announced a research collaboration with the Mayo Clinic to integrate Mayo Clinic Platform clinical and genomic datasets with Merck’s AI-enabled virtual cell technologies. The initial focus...

Korsana Therapeutics launched with $175 million in venture backing from investors including Wellington, Sanofi Ventures and a J.P. Morgan affiliate to advance KRSA‑028, an anti‑amyloid antibody...

Johnson & Johnson announced a more than $1 billion investment to build a cell‑therapy manufacturing facility in Pennsylvania as part of a broader push to expand its cell therapy capabilities. The...

University of Missouri researchers published PSBench, a curated database of 1.4 million protein structure models annotated and quality‑checked by independent experts. The resource is intended to...

Eli Lilly agreed to pay $100 million upfront to license rights from CSL for clazakizumab, an anti‑IL‑6 monoclonal antibody, expanding Lilly’s inflammation and immunology portfolio. CSL retains...

Danaher Corp. agreed to acquire Masimo Corp. for $9.9 billion in cash, paying $180 per share, a roughly 38% premium to Masimo’s last close. The transaction bolsters Danaher’s diagnostics and...

Gilead Sciences entered a licensing agreement with Genhouse Bio to acquire rights to a clinical‑ready MAT2A inhibitor designed to exploit synthetic lethality in MTAP‑deleted tumors. The deal is...

The FDA reversed a recent refusal and agreed to review Moderna’s BLA for its seasonal mRNA influenza vaccine, setting a PDUFA target of Aug. 5, 2026. The decision follows a Type A meeting in which...

Compass Pathways disclosed positive results from a second Phase III study of its synthetic psilocybin candidate COMP360 in treatment‑resistant depression, reporting statistically significant...

Novartis signed a research and licensing agreement with Unnatural Products (UNP) to access UNP’s AI‑guided macrocyclic peptide discovery platform in a collaboration that could generate up to...

Eli Lilly agreed to license rights from CSL Limited for clazakizumab, an IL‑6‑targeting monoclonal antibody, paying an initial $100 million with additional clinical, regulatory and commercial...

Korsana Therapeutics launched with $175 million in venture backing to advance an anti‑amyloid antibody program (KRSA‑028) spun out of Paragon Therapeutics. Investors include Wellington, Sanofi...

Merck and the Mayo Clinic announced a research and development collaboration to integrate Mayo Clinic Platform clinical and genomic datasets with Merck’s AI‑enabled virtual cell technologies. The...

Two independent reports from NYU Langone researchers revealed that cancer cells activate an integrated stress response (ISR) that triggers ATF4‑dependent secretion of lipocalin 2 (LCN2), which in...

Ocular Therapeutix reported Phase III results showing its investigational Axpaxli (OTX‑TKI) maintained visual acuity better than a low‑dose aflibercept (Eylea) control in wet age‑related macular...

Sensei Biotherapeutics acquired Faeth Therapeutics in a stock‑for‑stock deal that effectively folded Faeth into Sensei and raised about $200 million via a private placement. The acquisition brings...

FDA Commissioner Marty Makary warned that the United States is losing ground to China in early‑stage drug development and called for reforms to speed trial starts, citing bottlenecks in hospital...

The U.S. Food and Drug Administration reversed a refusal-to-file decision and agreed to review Moderna’s BLA for its seasonal mRNA influenza vaccine mRNA-1010, setting a PDUFA goal date of Aug. 5,...

Compass Pathways reported a second positive Phase III readout for its synthetic psilocybin candidate COMP360 in treatment-resistant depression, reinforcing efficacy signals from an earlier pivotal...

Novartis and Unnatural Products launched a research and licensing partnership to discover macrocyclic peptide therapeutics targeting cardiovascular disease and potentially undruggable proteins....